Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2007

01-07-2007 | Epidemiology

Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil

Authors: Magda C. B. Gomes, Mauricio M. Costa, Radovan Borojevic, Alvaro N. A. Monteiro, Roberto Vieira, Sergio Koifman, Rosalina Jorge Koifman, Song Li, Robert Royer, Shiyu Zhang, Steven A. Narod

Published in: Breast Cancer Research and Treatment | Issue 3/2007

Login to get access

Abstract

The contribution of BRCA1 and BRCA2 to breast cancer incidence in Brazil has not yet been explored. In order to estimate the proportion of breast cancers due to BRCA1 and BRCA2 mutations in Brazil, we conducted a study of unselected breast cancer patients from Rio de Janeiro, Brazil. We enrolled 402 women with breast cancer from a large public hospital and two private medical clinics in the city. A detailed family history was obtained from each patient and a blood sample was obtained for DNA analysis. Mutations in BRCA1 and BRCA2 were sought using a combination of techniques, but all mutations were confirmed by direct sequencing. Overall, nine mutations were identified (six in BRCA1 and three in BRCA2) representing 2.3% of the total. The most common mutation, 5382insC in BRCA1, was seen five times and accounted for 56% of all identified mutations. A second mutation, in BRCA2 (6633del5) was seen in two unrelated women. In summary, BRCA1 and BRCA2 mutations are not uncommon in Brazilian women with breast cancer. It appears that a small number of founder mutations may be predominant. Moreover, a small number of founder mutations may be prevalent in Brazil, raising the possibility that a rapid and inexpensive genetic test may be developed to screen for inherited susceptibility to breast cancer in Brazil.
Literature
1.
go back to reference Narod S, Ford D, Devilee P et al (1995) Genetic heterogeneity of breast–ovarian cancer revisited. Am J Hum Genet 57:957–958PubMed Narod S, Ford D, Devilee P et al (1995) Genetic heterogeneity of breast–ovarian cancer revisited. Am J Hum Genet 57:957–958PubMed
2.
go back to reference Koifman RJ, Koifman S, Vieria RJS (1998) Familial aggregation of breast/ovarian cancer age of onset along subsequent generations in Brazil. Cad Saude Publica 14(Suppl 3):181–185PubMed Koifman RJ, Koifman S, Vieria RJS (1998) Familial aggregation of breast/ovarian cancer age of onset along subsequent generations in Brazil. Cad Saude Publica 14(Suppl 3):181–185PubMed
3.
go back to reference Ford D, Easton DF, Bishop DT et al (1994) Risks of cancer in BRCA1-mutation carriers. Lancet 343:692–695PubMedCrossRef Ford D, Easton DF, Bishop DT et al (1994) Risks of cancer in BRCA1-mutation carriers. Lancet 343:692–695PubMedCrossRef
4.
go back to reference Thompson D, Easton D, Breast Cancer Linkage Consortium (2001) Variation in cancer risks by mutation position in BRCA2 mutation carriers. Am J Hum Genet 68:410–419PubMedCrossRef Thompson D, Easton D, Breast Cancer Linkage Consortium (2001) Variation in cancer risks by mutation position in BRCA2 mutation carriers. Am J Hum Genet 68:410–419PubMedCrossRef
5.
go back to reference Thompson D, Easton D, the Breast Cancer Linkage Consortium (2002) Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 11:329–336PubMed Thompson D, Easton D, the Breast Cancer Linkage Consortium (2002) Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 11:329–336PubMed
6.
go back to reference King M-C, Marks JH, Mandell JB et al (2003) Breast and ovarian cancer risks dud to inherited mutations in BRCA1 and BRCA2. Science 302:643–646PubMedCrossRef King M-C, Marks JH, Mandell JB et al (2003) Breast and ovarian cancer risks dud to inherited mutations in BRCA1 and BRCA2. Science 302:643–646PubMedCrossRef
7.
go back to reference Antoniou A, Pharoah PDP, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 and BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130PubMedCrossRef Antoniou A, Pharoah PDP, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 and BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130PubMedCrossRef
9.
go back to reference Kuperstein G, Foulkes WD, Ghadirian P et al (2000) A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes. Clin Genet 57:213–220PubMedCrossRef Kuperstein G, Foulkes WD, Ghadirian P et al (2000) A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes. Clin Genet 57:213–220PubMedCrossRef
10.
go back to reference The BRCA1 Exon 13 Duplication Screening Group (2000) The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. Am J Hum Genet 67:207–212CrossRef The BRCA1 Exon 13 Duplication Screening Group (2000) The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. Am J Hum Genet 67:207–212CrossRef
11.
go back to reference Kuperstein G, Jack E, Risch H et al (2006) A fluorescent multiplexed-DGGE (FMD) screening test for BRCA1 gene. Genet Test 10:1–7PubMedCrossRef Kuperstein G, Jack E, Risch H et al (2006) A fluorescent multiplexed-DGGE (FMD) screening test for BRCA1 gene. Genet Test 10:1–7PubMedCrossRef
12.
go back to reference Gross E, Arnold N, Pfeifer K et al (2000) Identification of specific BRCA1 and BRCA2 variants by DHPLC. Hum Mutat 16:345–353PubMedCrossRef Gross E, Arnold N, Pfeifer K et al (2000) Identification of specific BRCA1 and BRCA2 variants by DHPLC. Hum Mutat 16:345–353PubMedCrossRef
13.
go back to reference Ford D, Easton DF, Bishop DT et al (1994) Risks of cancer in BRCA1-mutation carriers. Lancet 343:692–695PubMedCrossRef Ford D, Easton DF, Bishop DT et al (1994) Risks of cancer in BRCA1-mutation carriers. Lancet 343:692–695PubMedCrossRef
14.
go back to reference Thompson D, Easton D, the Breast Cancer Linkage Consortium (2001) Variation in cancer risks by mutation position in BRCA2 mutation carriers. Am J Hum Genet 68:410–419PubMedCrossRef Thompson D, Easton D, the Breast Cancer Linkage Consortium (2001) Variation in cancer risks by mutation position in BRCA2 mutation carriers. Am J Hum Genet 68:410–419PubMedCrossRef
15.
go back to reference Thompson D, Easton D, the Breast Cancer Linkage Consortium (2002) Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 11:329–336PubMed Thompson D, Easton D, the Breast Cancer Linkage Consortium (2002) Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 11:329–336PubMed
16.
go back to reference King M-C, Marks JH, Mandell JB et al (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–646PubMedCrossRef King M-C, Marks JH, Mandell JB et al (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–646PubMedCrossRef
17.
go back to reference Dufloth RM, Carvalho S, Heinrich JK et al (2005) Analysis of BRCA1 and BRCA2 mutations in Brazilian breast cancer patients with positive family history. Sao Paulo Med J 123:192–197PubMedCrossRef Dufloth RM, Carvalho S, Heinrich JK et al (2005) Analysis of BRCA1 and BRCA2 mutations in Brazilian breast cancer patients with positive family history. Sao Paulo Med J 123:192–197PubMedCrossRef
18.
go back to reference Tonin P, Weber B, Offit K et al (1996) Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2:1179–1183PubMedCrossRef Tonin P, Weber B, Offit K et al (1996) Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2:1179–1183PubMedCrossRef
19.
go back to reference Gorski B, Byrski T, Huzarski T et al (2000) Founder mutations in BRCA1 gene in Polish families with breast–ovarian cancer. Am J Hum Genet 66:1963–1968PubMedCrossRef Gorski B, Byrski T, Huzarski T et al (2000) Founder mutations in BRCA1 gene in Polish families with breast–ovarian cancer. Am J Hum Genet 66:1963–1968PubMedCrossRef
20.
go back to reference Carvalho-Silva DR, Santos FR, Rocha J et al (2001) The phylogeography of Brazilian Y-chromosome lineages. Hum Genet 68:281–286CrossRef Carvalho-Silva DR, Santos FR, Rocha J et al (2001) The phylogeography of Brazilian Y-chromosome lineages. Hum Genet 68:281–286CrossRef
21.
go back to reference Jara L, Ampuero S, Santibanez E et al (2006) BRCA1 and BRCA2 mutations in a South American population. Cancer Cenet Cytogenet 166:36–45CrossRef Jara L, Ampuero S, Santibanez E et al (2006) BRCA1 and BRCA2 mutations in a South American population. Cancer Cenet Cytogenet 166:36–45CrossRef
22.
go back to reference Gallardo M, Silva A, Rubio L et al (2006) Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype–phenotype correlations. Breast Cancer Res Treat 95:81–87PubMedCrossRef Gallardo M, Silva A, Rubio L et al (2006) Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype–phenotype correlations. Breast Cancer Res Treat 95:81–87PubMedCrossRef
23.
go back to reference Risch HA, McLaughlin JR, Cole DEC et al (2001) Prevalance and penetrance of germline BRCA1 and BRCA1 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700–710PubMedCrossRef Risch HA, McLaughlin JR, Cole DEC et al (2001) Prevalance and penetrance of germline BRCA1 and BRCA1 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700–710PubMedCrossRef
24.
go back to reference Unger MA, Nathanson KL, Calzone K et al (2000) Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet 67:841–850PubMedCrossRef Unger MA, Nathanson KL, Calzone K et al (2000) Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet 67:841–850PubMedCrossRef
Metadata
Title
Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil
Authors
Magda C. B. Gomes
Mauricio M. Costa
Radovan Borojevic
Alvaro N. A. Monteiro
Roberto Vieira
Sergio Koifman
Rosalina Jorge Koifman
Song Li
Robert Royer
Shiyu Zhang
Steven A. Narod
Publication date
01-07-2007
Published in
Breast Cancer Research and Treatment / Issue 3/2007
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9378-6

Other articles of this Issue 3/2007

Breast Cancer Research and Treatment 3/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine